ZA200301015B - Selective cyclic peptides. - Google Patents
Selective cyclic peptides. Download PDFInfo
- Publication number
- ZA200301015B ZA200301015B ZA200301015A ZA200301015A ZA200301015B ZA 200301015 B ZA200301015 B ZA 200301015B ZA 200301015 A ZA200301015 A ZA 200301015A ZA 200301015 A ZA200301015 A ZA 200301015A ZA 200301015 B ZA200301015 B ZA 200301015B
- Authority
- ZA
- South Africa
- Prior art keywords
- lys
- asp
- hydrogen
- phe
- cyclo
- Prior art date
Links
- 102000001189 Cyclic Peptides Human genes 0.000 title description 3
- 108010069514 Cyclic Peptides Proteins 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 100
- 229910052739 hydrogen Inorganic materials 0.000 claims description 100
- 239000001257 hydrogen Substances 0.000 claims description 100
- 125000000217 alkyl group Chemical group 0.000 claims description 71
- 125000004432 carbon atom Chemical group C* 0.000 claims description 69
- 108010092854 aspartyllysine Proteins 0.000 claims description 58
- OAMLVOVXNKILLQ-BQBZGAKWSA-N Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O OAMLVOVXNKILLQ-BQBZGAKWSA-N 0.000 claims description 57
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 51
- 150000002431 hydrogen Chemical class 0.000 claims description 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 27
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 125000000304 alkynyl group Chemical group 0.000 claims description 12
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 9
- 208000008589 Obesity Diseases 0.000 claims description 8
- 235000020824 obesity Nutrition 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 claims description 4
- 108010004073 cysteinylcysteine Proteins 0.000 claims description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 229910019567 Re Re Inorganic materials 0.000 claims description 3
- -1 or Chemical group 0.000 claims description 3
- BBBXWRGITSUJPB-YUMQZZPRSA-N Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O BBBXWRGITSUJPB-YUMQZZPRSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 13
- 125000001475 halogen functional group Chemical group 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 7
- 239000000126 substance Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 102000001796 Melanocortin 4 receptors Human genes 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 241000735495 Erica <angiosperm> Species 0.000 claims 1
- 235000008694 Humulus lupulus Nutrition 0.000 claims 1
- 244000025221 Humulus lupulus Species 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000000556 agonist Substances 0.000 description 12
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 description 11
- 125000005843 halogen group Chemical group 0.000 description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 5
- 101710161100 Melanocyte-stimulating hormone receptor Proteins 0.000 description 5
- 102000004378 Melanocortin Receptors Human genes 0.000 description 4
- 108090000950 Melanocortin Receptors Proteins 0.000 description 4
- 230000008484 agonism Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 2
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- JDKLPDJLXHXHNV-MFVUMRCOSA-N (3s,6s,9r,12s,15s,23s)-15-[[(2s)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1h-imidazol-5-ylmethyl)-3-(1h-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxamide Chemical compound C([C@@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCNC(=O)C[C@@H](C(N[C@@H](CC=2NC=NC=2)C(=O)N1)=O)NC(=O)[C@@H](NC(C)=O)CCCC)C(N)=O)C1=CC=CC=C1 JDKLPDJLXHXHNV-MFVUMRCOSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 102100022455 Adrenocorticotropic hormone receptor Human genes 0.000 description 1
- 101710115814 Adrenocorticotropic hormone receptor Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229940126661 MC4 antagonist Drugs 0.000 description 1
- 102100023726 Melanocortin receptor 3 Human genes 0.000 description 1
- 101710085774 Melanocortin receptor 3 Proteins 0.000 description 1
- 102100023723 Melanocortin receptor 5 Human genes 0.000 description 1
- 101710085771 Melanocortin receptor 5 Proteins 0.000 description 1
- 108010008364 Melanocortins Proteins 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 101710201349 Metallothionein B Proteins 0.000 description 1
- 102100031347 Metallothionein-2 Human genes 0.000 description 1
- 101710094505 Metallothionein-2 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100274389 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) chz-1 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- YQNBKXUTWBRQCS-BVSLBCMMSA-N Phe-Arg-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 YQNBKXUTWBRQCS-BVSLBCMMSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000270942 Rana pipiens Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 108010042362 beta-Lipotropin Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000002865 melanocortin Substances 0.000 description 1
- 230000001802 melanotrophic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 210000000211 third ventricle Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/68—Melanocyte-stimulating hormone [MSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22918400P | 2000-08-30 | 2000-08-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200301015B true ZA200301015B (en) | 2004-05-05 |
Family
ID=22860145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200301015A ZA200301015B (en) | 2000-08-30 | 2003-02-05 | Selective cyclic peptides. |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US7045591B2 (fr) |
| EP (1) | EP1315750B1 (fr) |
| JP (1) | JP4217069B2 (fr) |
| KR (1) | KR100483300B1 (fr) |
| CN (1) | CN100491396C (fr) |
| AR (2) | AR030504A1 (fr) |
| AT (1) | ATE353918T1 (fr) |
| AU (2) | AU2001284026B2 (fr) |
| BR (1) | BR0113637A (fr) |
| CA (1) | CA2420058C (fr) |
| CY (1) | CY1106562T1 (fr) |
| CZ (1) | CZ2003584A3 (fr) |
| DE (1) | DE60126624T2 (fr) |
| DK (1) | DK1315750T3 (fr) |
| EC (1) | ECSP034503A (fr) |
| ES (1) | ES2280393T3 (fr) |
| HR (1) | HRP20030126B1 (fr) |
| HU (1) | HUP0303078A3 (fr) |
| IL (2) | IL154575A0 (fr) |
| JO (1) | JO2454B1 (fr) |
| MA (1) | MA27681A1 (fr) |
| MX (1) | MXPA03001721A (fr) |
| MY (1) | MY137457A (fr) |
| NO (1) | NO20030916D0 (fr) |
| NZ (1) | NZ523989A (fr) |
| PA (1) | PA8527201A1 (fr) |
| PE (1) | PE20020483A1 (fr) |
| PL (1) | PL366630A1 (fr) |
| PT (1) | PT1315750E (fr) |
| RU (1) | RU2239642C1 (fr) |
| SI (1) | SI1315750T1 (fr) |
| TW (1) | TWI248941B (fr) |
| WO (1) | WO2002018437A2 (fr) |
| YU (1) | YU15603A (fr) |
| ZA (1) | ZA200301015B (fr) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1409521A2 (fr) * | 2001-07-12 | 2004-04-21 | Merck & Co., Inc. | Peptides cycliques agonistes puissants et selectifs de recepteur de melanocortine-4 |
| WO2003013571A1 (fr) | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetiques de metallopeptides biologiquement actifs |
| US7655658B2 (en) | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
| US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| US7354923B2 (en) * | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
| US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| US7732451B2 (en) | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
| BR0305628A (pt) | 2002-07-09 | 2004-09-08 | Palatin Technologies Inc | Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso |
| US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
| US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
| US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
| KR20060026011A (ko) | 2003-05-09 | 2006-03-22 | 노보 노르디스크 에이/에스 | 비만 치료용 펩티드 |
| AU2004235872A1 (en) * | 2003-05-09 | 2004-11-18 | Novo Nordisk A/S | Peptides for use in treating obesity |
| US20060293223A1 (en) * | 2003-06-19 | 2006-12-28 | Eli Lilly And Company Patent Division | Uses of melanocortin-3 receptor (mc3r) agonist peptides |
| KR20060014444A (ko) * | 2003-06-19 | 2006-02-15 | 일라이 릴리 앤드 캄파니 | 멜라노코르틴 수용체 4 (ｍｃ4) 작용제 및 그의 용도 |
| US7084111B2 (en) | 2003-06-23 | 2006-08-01 | University Of Florida Research Foundation, Inc. | Melanocortin receptor templates, peptides, and use thereof |
| MXPA06003474A (es) | 2003-09-30 | 2006-06-05 | Novo Nordisk As | Agonistas de receptores de melanocortina. |
| US7550602B1 (en) | 2004-01-14 | 2009-06-23 | Palatin Technologies, Inc. | Small molecule compositions for sexual dysfunction |
| US6974187B2 (en) * | 2004-01-28 | 2005-12-13 | Tachi-S Co., Ltd. | Vehicle seat structure |
| EP1732586A1 (fr) * | 2004-03-29 | 2006-12-20 | Eli Lilly And Company | Utilisations de peptides agonistes du recepteur de la melanocortine 4 (mc4r) administres par perfusion continue |
| KR101092716B1 (ko) * | 2004-04-08 | 2011-12-09 | 아스테라스 세이야쿠 가부시키가이샤 | 화합물 ｗｓ727713 |
| US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| US20110098213A1 (en) * | 2004-11-04 | 2011-04-28 | Novo Nordisk A/S | Novel peptides for use in the treatment of obesity |
| US20080039387A1 (en) * | 2004-11-04 | 2008-02-14 | Novo Nordisk A/S | Novel Peptides for Use in the Treatment of Obesity |
| WO2006048452A2 (fr) * | 2004-11-04 | 2006-05-11 | Novo Nordisk A/S | Nouveaux peptides utiles dans le traitement de l'obesite |
| JP2008519008A (ja) * | 2004-11-04 | 2008-06-05 | ノボ ノルディスク アクティーゼルスカブ | 肥満症の治療に使用するためのペプチド |
| CN101203527A (zh) * | 2005-05-31 | 2008-06-18 | 耶路撒冷希伯来大学伊森姆研究发展公司 | 主链环化的促黑皮质素激素（αMSH）类似物 |
| CA2611836A1 (fr) * | 2005-06-13 | 2006-12-21 | Nastech Pharmaceutical Company Inc. | Administration transmucosale de derives peptidiques |
| US7671112B2 (en) * | 2005-07-15 | 2010-03-02 | 3M Innovative Properties Company | Method of making fluoropolymer dispersion |
| US20080015304A1 (en) | 2006-07-13 | 2008-01-17 | Klaus Hintzer | Aqueous emulsion polymerization process for producing fluoropolymers |
| GB2430437A (en) * | 2005-09-27 | 2007-03-28 | 3M Innovative Properties Co | Method of making a fluoropolymer |
| US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
| CA2673229A1 (fr) * | 2006-12-29 | 2008-07-10 | F. Hoffmann-La Roche Ag | Procedes de synthese de peptides cycliques |
| JP5226701B2 (ja) * | 2007-02-16 | 2013-07-03 | スリーエム イノベイティブ プロパティズ カンパニー | 水からフッ素性化学物質を除去するためのシステム及びプロセス |
| US20080264864A1 (en) | 2007-04-27 | 2008-10-30 | 3M Innovative Properties Company | PROCESS FOR REMOVING FLUORINATED EMULSIFIER FROM FLUOROPOLMER DISPERSIONS USING AN ANION-EXCHANGE RESIN AND A pH-DEPENDENT SURFACTANT AND FLUOROPOLYMER DISPERSIONS CONTAINING A pH-DEPENDENT SURFACTANT |
| WO2008147556A2 (fr) * | 2007-05-25 | 2008-12-04 | Ipsen Pharma S.A.S. | Ligands de récepteurs de la mélanocortine modifiés au moyen d'hydantoïne |
| EP2172459B1 (fr) | 2007-07-19 | 2014-03-19 | Tokuyama Corporation | Composé ayant un cycle hydantoïne et son procédé de fabrication |
| NZ588779A (en) | 2008-03-27 | 2012-06-29 | Gruenenthal Chemie | Substituted 4-aminocyclohexane derivatives |
| JP5650637B2 (ja) * | 2008-03-27 | 2015-01-07 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | （ヘテロ−）アリール−シクロヘキサン誘導体 |
| US20090305960A1 (en) * | 2008-06-09 | 2009-12-10 | Palatin Technologies, Inc | Melanocortin Receptor-Specific Peptides for Treatment of Obesity / 669 |
| WO2009152079A1 (fr) | 2008-06-09 | 2009-12-17 | Palatin Technologies, Inc. | Peptides spécifiques du récepteur de mélanocortine pour le traitement d'un dysfonctionnement sexuel |
| UY32690A (es) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
| WO2010144341A2 (fr) | 2009-06-08 | 2010-12-16 | Palatin Technologies, Inc. | Peptides spécifiques des récepteurs aux mélanocortines à pont lactame |
| EA020959B1 (ru) | 2009-06-08 | 2015-03-31 | Палатин Текнолоджиз, Инк. | Пептиды, специфичные к меланокортиновым рецепторам |
| CA2781405A1 (fr) | 2009-11-23 | 2011-05-26 | Palatin Technologies, Inc. | Peptides lineaires specifiques du recepteur de la melanocortine-1 |
| NZ599774A (en) | 2009-11-23 | 2014-11-28 | Palatin Technologies Inc | Melanocortin-1 receptor-specific cyclic peptides |
| JP6622690B2 (ja) * | 2013-03-15 | 2019-12-18 | リズム・ファーマシューティカルズ・インコーポレイテッド | ペプチド組成物 |
| GB201416352D0 (en) | 2014-09-16 | 2014-10-29 | Shire Internat Gmbh | Spirocyclic derivatives |
| GB201416351D0 (en) * | 2014-09-16 | 2014-10-29 | Shire Internat Gmbh | Heterocyclic derivatives |
| AU2015323769A1 (en) * | 2014-09-26 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Stabilized adrenomedullin derivatives and use thereof |
| US11542302B2 (en) | 2015-10-15 | 2023-01-03 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Modulators of melanocortin receptors for the treatment of depression and anxiety |
| WO2018074999A1 (fr) * | 2016-10-17 | 2018-04-26 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Nouveaux modulateurs des récepteurs de mélanocortine pour le traitement de la dépression et de l'anxiété |
| WO2017066754A1 (fr) | 2015-10-15 | 2017-04-20 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions et méthodes de traitement de la dépression et de l'anxiété |
| US10899793B2 (en) | 2016-05-27 | 2021-01-26 | Regents Of The University Of Minnesota | Melanocortin ligands and methods of use thereof |
| US11124541B2 (en) | 2016-10-18 | 2021-09-21 | Regents Of The University Of Minnesota | Chimeric melanocortin ligands and methods of use thereof |
| CN106496005B (zh) * | 2016-10-20 | 2019-04-09 | 上海毕得医药科技有限公司 | 一种4-(4-氯苯基)环己酮的合成方法 |
| CN106496008A (zh) * | 2016-10-20 | 2017-03-15 | 上海毕得医药科技有限公司 | 一种合成4‑(4‑氯苯基)环己酮的方法 |
| US10745444B2 (en) * | 2017-04-17 | 2020-08-18 | National Tsing Hua University | Cyclopeptide, pharmaceutical or cosmetic composition comprising the same and method for preparing the same |
| US11332499B2 (en) | 2018-08-16 | 2022-05-17 | Regents Of The University Of Minnesota | Cyclic peptides and methods of use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
| US5858972A (en) | 1996-01-11 | 1999-01-12 | La Jolla Cancer Research Foundation | Antithrombotic agents and methods of use |
| HUP0202203A3 (en) | 1999-03-29 | 2003-09-29 | Procter & Gamble | Melanocortin receptor ligands, pharmaceutical compositions comprising thereof and method for their preparation |
-
2001
- 2001-08-21 MX MXPA03001721A patent/MXPA03001721A/es active IP Right Grant
- 2001-08-21 KR KR10-2003-7002931A patent/KR100483300B1/ko not_active IP Right Cessation
- 2001-08-21 IL IL15457501A patent/IL154575A0/xx unknown
- 2001-08-21 AT AT01962958T patent/ATE353918T1/de active
- 2001-08-21 YU YU15603A patent/YU15603A/sh unknown
- 2001-08-21 PL PL01366630A patent/PL366630A1/xx not_active Application Discontinuation
- 2001-08-21 CN CNB018150284A patent/CN100491396C/zh not_active Expired - Fee Related
- 2001-08-21 JP JP2002523951A patent/JP4217069B2/ja not_active Expired - Fee Related
- 2001-08-21 HU HU0303078A patent/HUP0303078A3/hu unknown
- 2001-08-21 DK DK01962958T patent/DK1315750T3/da active
- 2001-08-21 PT PT01962958T patent/PT1315750E/pt unknown
- 2001-08-21 CA CA002420058A patent/CA2420058C/fr not_active Expired - Fee Related
- 2001-08-21 DE DE60126624T patent/DE60126624T2/de not_active Expired - Lifetime
- 2001-08-21 CZ CZ2003584A patent/CZ2003584A3/cs unknown
- 2001-08-21 BR BR0113637-2A patent/BR0113637A/pt not_active IP Right Cessation
- 2001-08-21 AU AU2001284026A patent/AU2001284026B2/en not_active Ceased
- 2001-08-21 ES ES01962958T patent/ES2280393T3/es not_active Expired - Lifetime
- 2001-08-21 NZ NZ523989A patent/NZ523989A/en unknown
- 2001-08-21 EP EP01962958A patent/EP1315750B1/fr not_active Expired - Lifetime
- 2001-08-21 AU AU8402601A patent/AU8402601A/xx active Pending
- 2001-08-21 WO PCT/EP2001/009630 patent/WO2002018437A2/fr active IP Right Grant
- 2001-08-21 RU RU2003107921/04A patent/RU2239642C1/ru not_active IP Right Cessation
- 2001-08-21 SI SI200130703T patent/SI1315750T1/sl unknown
- 2001-08-23 JO JO2001138A patent/JO2454B1/en active
- 2001-08-27 US US09/939,966 patent/US7045591B2/en not_active Expired - Fee Related
- 2001-08-28 MY MYPI20014025A patent/MY137457A/en unknown
- 2001-08-28 PA PA20018527201A patent/PA8527201A1/es unknown
- 2001-08-28 AR ARP010104096A patent/AR030504A1/es active IP Right Grant
- 2001-08-28 PE PE2001000859A patent/PE20020483A1/es not_active Application Discontinuation
- 2001-08-30 TW TW090121400A patent/TWI248941B/zh not_active IP Right Cessation
-
2003
- 2003-02-05 ZA ZA200301015A patent/ZA200301015B/en unknown
- 2003-02-20 IL IL154575A patent/IL154575A/en not_active IP Right Cessation
- 2003-02-20 HR HR20030126A patent/HRP20030126B1/xx not_active IP Right Cessation
- 2003-02-27 NO NO20030916A patent/NO20030916D0/no not_active Application Discontinuation
- 2003-02-27 MA MA27059A patent/MA27681A1/fr unknown
- 2003-03-06 EC EC2003004503A patent/ECSP034503A/es unknown
-
2007
- 2007-05-07 CY CY20071100594T patent/CY1106562T1/el unknown
- 2007-05-30 AR ARP070102336A patent/AR061422A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200301015B (en) | Selective cyclic peptides. | |
| US7795378B2 (en) | Peptide compositions for treatment of sexual dysfunction | |
| JP5965520B2 (ja) | メラノコルチン受容体リガンド | |
| DE60038734T2 (de) | Melanocortinrezeptor-liganden | |
| AU783718B2 (en) | Compositions and methods for treatment of sexual dysfunction | |
| US7473760B2 (en) | Cyclic peptide compositions for treatment of sexual dysfunction | |
| US7342089B2 (en) | Cyclic peptides for treatment for cachexia | |
| RU2381233C2 (ru) | Агонисты рецептора меланокортина | |
| TW458958B (en) | Compound with growth hormone releasing properties | |
| TWI364290B (en) | Melanocortin receptor ligands modifled with hydantoin | |
| CA1268597A (fr) | Derives de diamino-acide | |
| EP2473518B1 (fr) | Ligands de mélanocortine stabilisés | |
| CA2574605A1 (fr) | Peptides cycliques destines au traitement de la cachexie | |
| US20110009341A1 (en) | N-Alkylated Cyclic Peptide Melanocortin Agonists | |
| US7307063B2 (en) | Melanocortin metallopeptides for treatment of sexual dysfunction | |
| EP2029617A2 (fr) | N-oxydes de peptides de récepteurs de kappa-opioïdes | |
| AU602657B2 (en) | Therapeutic somatostatin analogs | |
| EP0222283A2 (fr) | Dérivés d'acides aminés | |
| Bednarek et al. | Ligands of the melanocortin receptors, 2002–2003 update | |
| US6228841B1 (en) | Peptide derivatives | |
| JPS61293999A (ja) | バソプレシン拮抗剤 | |
| WO1992021366A1 (fr) | Pentapeptides neuromediateurs et immuno-regulateurs | |
| CH632486A5 (de) | Verfahren zur herstellung von tetradecapeptiden. | |
| WO2002000688A1 (fr) | Compose peptidique, compositions pharmaceutiques et medicaments contenant ceux-ci comme principe actif |